Avibactam is a non β-lactam β-lactamase inhibitor developed to combat antibiotic resistance in bacterial infections. Approved by the FDA in February 2015, it is commonly used in combination with other antibiotics to treat complicated infections. 

Clinical trials demonstrated its efficacy against multidrug-resistant organisms, particularly gram-negative bacteria, offering hope in an era of rising antimicrobial resistance. Avibactam has undergone rigorous testing in pivotal Phase III trials, showcasing its potential to restore the activity of β-lactam antibiotics against resistant pathogens.

Avibactam is FDA-approved for use in combination with other antibiotics to treat:

• Complicated intra-abdominal infections (cIAI)
• Complicated urinary tract infections (cUTI), including pyelonephritis
• Hospital-acquired bacterial pneumonia (HABP)
• Ventilator-associated bacterial pneumonia (VABP)

Common Side Effects

• Diarrhea
• Nausea and vomiting
• Headache
• Rash or itching at the injection site

Serious Side Effects

• Anaphylaxis (severe allergic reactions)
• Clostridioides difficile-associated diarrhea
• Seizures (rare, but significant)
• Elevated liver enzymes (indicating liver stress)

• Severe Allergic Reactions: Avoid use in individuals with a history of hypersensitivity to β-lactam antibiotics.
• Renal Impairment: Dosage adjustments are critical for patients with compromised kidney function.
• Seizures: Risk increases in patients with central nervous system disorders.
• Drug Interactions: Avoid concurrent use with other nephrotoxic agents.
• Pregnancy and Lactation: Use only if clearly needed and under medical supervision.

Before administering this medication, it is essential to assess the patient’s medical history, including any known allergies to penicillin or cephalosporin antibiotics. Regular renal function monitoring is advised, as improper clearance can increase toxicity risks. Administer the drug under strict medical supervision, ensuring aseptic techniques for intravenous infusion. Pregnant and breastfeeding individuals should consult a healthcare provider to weigh potential risks and benefits.

Avibactam should only be used under a healthcare provider’s guidance. Maintain adequate hydration during treatment and report any unusual symptoms immediately, such as severe diarrhea or allergic reactions. Avoid self-medicating or altering dosages without consulting a doctor. Patients with existing kidney conditions should undergo regular renal monitoring during therapy. Ensure to complete the full prescribed course to prevent resistance.

1. https://go.drugbank.com/drugs/DB09060
2. https://pubchem.ncbi.nlm.nih.gov/compound/Avibactam
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC4187909/
4. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/avibactam

This content is for informational purposes only and should not substitute professional medical advice. Always consult a licensed healthcare provider for guidance specific to your health condition.